ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1652

Progression of Knee OA with Use of Intra-articular Corticosteroids (CS) vs Hyaluronic Acid (HA)

Justin Bucci1, Xiaoyang Chen1, James Torner2, Michael Nevitt3, Cora Lewis4 and David Felson5, 1Boston University, Boston, MA, 2University of Iowa, Iowa City, IA, 3University of California, San Francisco, Orinda, CA, 4University of Alabama Birmingham, Birmingham, AL, 5Boston University School of Medicine, Boston, MA

Meeting: ACR Convergence 2020

Keywords: Cartilage Degradation, corticosteroids, Hyaluronan, Osteoarthritis, Total joint replacement

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Osteoarthritis – Clinical Poster II

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Recent studies have questioned whether CS injections (CSI), a popular treatment recommended by guidelines, hasten progression of knee OA.  A recent cohort study suggested a three-fold higher risk for knee OA progression with CSI.

A limitation of such studies is CSI recipients have more advanced knee OA, which is itself a risk factor for OA progression, making it impossible, despite statistical adjustments, to compare those undergoing CSI to those who do not report injections.  Patients receiving HA injections (HAI) are a natural comparator to those receiving CSI, as HAI has not been associated with cartilage loss.  The purpose of this study was to assess whether CSI was associated with increased rates on knee OA progression in comparison to HAI.

Methods: We used 2 cohort studies of knee OA, MOST and OAI, to look at rates of x-ray progression and total knee replacement (TKR) among CSI or HAI recipients.   OAI and MOST visits were performed every 12 and 30 months, respectively, and included knee x-rays and questions about HAI or CSI in the preceding 6 months.  The studies use similar acquisition and reading protocols.  Kellgren and Lawrence grades (KL) (0-4), joint space narrowing (JSN) (0-3) were scored for both studies and in OAI, medial joint space (JWS250) was measured.

For analysis of x-ray progression, we excluded knees with baseline KL 4, CSI or HAI reported at first visit, and recipients of HAI and CSI.  We compared x-rays from the visit before first reported injection to x-rays at the visit after the last injection.  TKR without post-injection x-ray was assigned KL grade 4 and JSN 3 at visit at which TKR was first present.  Annualized deterioration rates were calculated for KL, JSN and JWS250.  Using multivariable linear regression, we examined  deterioration rates for reports of injections at  single and multiple exams adjusting for age, sex, BMI, study, and baseline KL grade.  For TKR survival analysis, we added subjects who reported injections at baseline visits.  TKR events were censored after 7 years from first reported injection.

Results: 792 knees were analyzed, of which 647 reported CSI use and 145 reported HAI use.  124 reported CSI  and 19 reported HAI at >1 visit.  For additional characteristics, see table 1.

Unadjusted analysis for time to TKR is shown in figure 1.  The rate of TKR was greater among those with single exam reports of HAI than of CSI (p=.04) but not different for those reporting at multiple exams, although numbers were small. Multivariable analysis showed similar rates of radiographic progression  between CSI and HAI among subjects reporting injections at single or multiple exams (table 2).

Conclusion: CSI for knee OA was not associated with higher rate of radiographic progression or progression to TKR than HAI.  The risk of disease progression attributed to CSI in earlier studies may reflect the presence of more severe OA in those undergoing injections.

Table 1

Table 2

Figure 1


Disclosure: J. Bucci, None; X. Chen, None; J. Torner, None; M. Nevitt, None; C. Lewis, None; D. Felson, None.

To cite this abstract in AMA style:

Bucci J, Chen X, Torner J, Nevitt M, Lewis C, Felson D. Progression of Knee OA with Use of Intra-articular Corticosteroids (CS) vs Hyaluronic Acid (HA) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/progression-of-knee-oa-with-use-of-intra-articular-corticosteroids-cs-vs-hyaluronic-acid-ha/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/progression-of-knee-oa-with-use-of-intra-articular-corticosteroids-cs-vs-hyaluronic-acid-ha/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology